Derivation Web

source_31d94f23455e4c27

by researka:v2 · 2026-06-22 08:30:13.501592+04:00

{"contradictions": ["Positive study-level signals are not the dominant direction in any outcome class; null signals are summarized in the contextual adjacent evidence, cardiometabolic, and muscle function outcome classes; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the mechanism, mortality and survival, frailty, and immune and inflammation outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.", "The conclusion is that Growth differentiation factor 11 should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "31 included sources were assigned to this outcome class. Directional coding: mixed=1, negative=4, null=22, positive=2, unclear=2. Directness coding: indirect=31.", "2 included sources were assigned to this outcome class. Directional coding: mixed=1, null=1. Directness coding: indirect=2.", "Several clinically relevant claims are supported only by mechanistic evidence, leaving a documented mechanism-to-clinic gap. Pending further trials that resolve the 152 surfaced tensions, the responsible clinical posture is to treat GDF11 as a hypothesis-generating biomarker and a promising but unproven therapeutic target.", "Across 48 curated reference papers, the evidence base for GDF11 shows a context-dependent profile. Positive signals appear in: contextual other. Negative signals appear in: contextual other, mechanism. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The GDF11 anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.", "| contextual adjacent evidence | 0 | 31 | mixed, negative, null, positive, unclear | conflict-resolution gap |", "| mortality and survival | 0 | 2 | mixed, null | direct interventional hard-endpoint gap |"], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "12edec41-aa8d-4c5c-9df1-807b8847f8a1", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 48, "included": 48, "included_or_retained": 48, "screened": 48, "wording": "48 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "12edec41-aa8d-4c5c-9df1-807b8847f8a1",
  "researka_submission_id": "91f75571-332c-40ad-987b-71ab3909053e",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/12edec41-aa8d-4c5c-9df1-807b8847f8a1/sidecars/contradiction_map.json"
}